Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab as an Anti-depressant in MDD
NCT07845604Phase 2Recruiting
- Start
- Sep 2026
- Primary completion
- Jul 2031
- Countries
- 1
01
Overview
A Phase 2 trial of adalimumab in major depressive disorder (MDD). Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07845604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07845604.